Current Report Filing (8-k)
August 15 2022 - 02:35PM
Edgar (US Regulatory)
0001348362false00013483622022-08-102022-08-10iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported)
August 10,
2022
LEXARIA BIOSCIENCE
CORP.
|
(Exact name of registrant as specified in its charter)
|
Nevada
|
|
000-52138
|
|
20-2000871
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
100 – 740 McCurdy Road, Kelowna, BC Canada
|
|
V1X 2P7
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code
(250)
765-6424
_____________________________________
(Former name or former address, if changed since last
report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
Warrants to Purchase Common Stock
|
|
LEXX
LEXXW
|
|
The Nasdaq Capital Market
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 8.01 Other Events
Investigational New
Drug (“IND”) Application Progress
Lexaria Bioscience Corp. (“Lexaria”) received a positive full
written response from the Food and Drug Administration (“FDA”) from
its pre-Investigational New Drug (“Pre-IND”) meeting regarding
DehydraTECH-CBD for the treatment of hypertension.
The FDA confirmed that it agreed with Lexaria’s proposal to pursue
a 505(b)(2) new drug application (“NDA”) regulatory pathway for its
program which is advantageous because this abbreviated pathway, as
it is often described, typically enables a faster route to
commercial approval than the traditional 505(b)(1) NDA pathway.
Lexaria’s proposed Phase Ib clinical protocol for DehydraTECH-CBD
for treatment of a target of 100 patients with hypertension was
received favorably by the FDA, with a view to opening the IND
application to allow Lexaria to work towards full registration of
DehydraTECH-CBD for treatment of hypertension.
In addition, the FDA agreed that additional non-clinical studies
were not required prior to initiation of the DehydraTECH-CBD IND
program, given the compelling data already presented by Lexaria and
others regarding the safety and tolerability of CBD.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
LEXARIA BIOSCIENCE CORP.
|
|
|
|
/s/ Chris Bunka
|
|
Chris Bunka
|
|
CEO, Principal Executive Officer
|
|
|
|
Date: August 15, 2022
|
|
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Dec 2022 to Jan 2023
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Jan 2022 to Jan 2023